Want to join the conversation?
Pharmaceutical company $CELG said its subsidiary, Celgene International Sarl, announced that the European Commission (EC) has approved REVLIMID for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL), a rare type of aggressive non-Hodgkin's lymphoma, which starts in lymph nodes but can move to other organs causing tumors.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?